Published in J Cell Mol Med on November 20, 2016
CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol (2004) 5.21
Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology (2004) 4.05
Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol (2009) 2.57
Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther (2011) 2.42
Irritable bowel syndrome: a clinical review. JAMA (2015) 2.26
Meta-analysis: The treatment of irritable bowel syndrome. Aliment Pharmacol Ther (2004) 2.23
The epidemiology of irritable bowel syndrome. Clin Epidemiol (2014) 2.06
Intestinal mucosal mast cells in normal and nematode-infected rat intestines are in intimate contact with peptidergic nerves. Proc Natl Acad Sci U S A (1987) 1.94
International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol Rev (2003) 1.79
Long-term alterations of colonic nerve-mast cell interactions induced by neonatal maternal deprivation in rats. Gut (2008) 1.79
Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet (2003) 1.74
Activation of corticotropin-releasing factor receptor 2 mediates the colonic motor coping response to acute stress in rodents. Gastroenterology (2011) 1.71
Stress-induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells. Neurogastroenterol Motil (1997) 1.50
CRF receptor type 1 and 2 expression and anatomical distribution in the rat colon. J Neurochem (2004) 1.30
Stress-induced changes in intestinal transit in the rat: a model for irritable bowel syndrome. Gastroenterology (1988) 1.26
Stress and visceral pain: from animal models to clinical therapies. Exp Neurol (2011) 1.25
Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? Am J Physiol Gastrointest Liver Physiol (2009) 1.24
Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut (2008) 1.24
Cortagine, a CRF1 agonist, induces stresslike alterations of colonic function and visceral hypersensitivity in rodents primarily through peripheral pathways. Am J Physiol Gastrointest Liver Physiol (2009) 1.11
Peripheral corticotropin releasing factor (CRF) and a novel CRF1 receptor agonist, stressin1-A activate CRF1 receptor expressing cholinergic and nitrergic myenteric neurons selectively in the colon of conscious rats. Neurogastroenterol Motil (2007) 1.08
Corticotropin-releasing factor receptor 1-deficient mice show decreased anxiety and colonic sensitivity. Neurogastroenterol Motil (2007) 1.00
Otilonium bromide inhibits calcium entry through L-type calcium channels in human intestinal smooth muscle. Neurogastroenterol Motil (2004) 0.96
Otilonium bromide inhibits muscle contractions via L-type calcium channels in the rat colon. Neurogastroenterol Motil (2004) 0.91
Mechanisms of action of otilonium bromide (OB) in human cultured smooth muscle cells and rat colonic strips. Neurogastroenterol Motil (2013) 0.91
A distribution study with (14)C-otilonium bromide in the rat: evidence for selective tropism for large intestine after oral administration. Drug Metab Dispos (2000) 0.90
Receptor binding profile of Otilonium bromide. Pharmacol Res (1998) 0.89
IBS and the role of otilonium bromide. Int J Colorectal Dis (2012) 0.89
Clinical and functional evaluation of the efficacy of otilonium bromide: a multicenter study in Italy. Ital J Gastroenterol (1991) 0.88
Otilonium bromide enhances sensory thresholds of volume and pressure in patients with irritable bowel syndrome. J Physiol Paris (2001) 0.88
Expression of corticotropin releasing factor receptor type 1 (CRF1) in the human gastrointestinal tract and upregulation in the colonic mucosa in patients with ulcerative colitis. Peptides (2012) 0.87
Benefits from long-term treatment in irritable bowel syndrome. Gastroenterol Res Pract (2012) 0.86
Effect of otilonium bromide and ibodutant on the internalization of the NK2 receptor in human colon. Neurogastroenterol Motil (2011) 0.84
Calcitonin gene-related peptide-immunoreactive nerve fibres in the small intestine of the guinea-pig: electron-microscopic immunocytochemistry. Cell Tissue Res (1986) 0.84
Chronic treatment with otilonium bromide induces changes in L-type Ca²⁺ channel, tachykinins, and nitric oxide synthase expression in rat colon muscle coat. Neurogastroenterol Motil (2013) 0.83
The role of experimental models in developing new treatments for irritable bowel syndrome. Expert Rev Gastroenterol Hepatol (2011) 0.83
Colonic smooth muscle cells and colonic motility patterns as a target for irritable bowel syndrome therapy: mechanisms of action of otilonium bromide. Therap Adv Gastroenterol (2014) 0.82
Capsaicin receptor as target of calcitonin gene-related peptide in the gut. Prog Drug Res (2014) 0.80
Inner and outer portions of colonic circular muscle: ultrastructural and immunohistochemical changes in rat chronically treated with otilonium bromide. PLoS One (2014) 0.78
Changes in nitrergic and tachykininergic pathways in rat proximal colon in response to chronic treatment with otilonium bromide. Neurogastroenterol Motil (2015) 0.77
Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment. F1000Res (2016) 0.77
Changes of excitatory and inhibitory neurotransmitters in the colon of rats underwent to the wrap partial restraint stress. Neurogastroenterol Motil (2016) 0.76